C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study

Abstract

This short-term pilot study showed an improvement in the slope of the UPCR, with ∼50% improvement in three of seven patients with IgAN. Longer avacopan treatment duration may be indicated for maximal benefit.